Background: GnRH analogues are the treatment of choice for central precocious puberty. It has been proven beneficial effects on final adult height, but the reproductive function has many debate especially about PCOS. The criteria used for the diagnosis of PCOS can be more difficult to judge because it is not uniform between the studies.
Method: The Medline, Cochrane, EMBASE, Web of Science, SCOPUS data bases were searched for studies published up to January 22, 2016 using key phrases precocious puberty/early puberty, and GnRH analogue. We were unified in 2003 Rotterdam criteria to the diagnostic criteria for PCOS.
Results: The initial literature search yielded 3254 articles after the removal of duplicates. Of these, 3223 were excluded as not meeting inclusion criteria or non-relevant, leaving 31 reports for full-text review to assess eligibility.
Conclusion: Based on the studied literature, CPP patients with GnRH analogue treatment has a regular menstrual cycle at 80.5%. The available evidence supports little confidence regarding the impact of CPP with or without GnRH analogues on the develop of PCOS but suggests that early puberty in girls may increase the risk of PCOS. In order to increase the strength of the results, well-designed cohort studies with large sample size should be performed in future.
10 - 12 Sep 2016
European Society for Paediatric Endocrinology